What's Happening?
OrganaBio, a cell therapy contract development and manufacturing organization, has acquired the operating assets of Excellos Inc., expanding its capabilities across the United States. This acquisition establishes OrganaBio as a bicoastal entity with facilities
in Miami, San Francisco, Irvine, and now San Diego. The integration of Excellos' facilities, including five ISO 7 cGMP cleanroom suites, enhances OrganaBio's ability to provide comprehensive cell therapy services, including manufacturing, cell isolation, and cryopreservation. The acquisition aims to address supply chain risks and improve service quality for cell therapy developers.
Why It's Important?
The acquisition of Excellos by OrganaBio is a strategic move that strengthens the company's position in the cell therapy market. By expanding its geographic footprint and service offerings, OrganaBio can better meet the needs of its clients, including many top pharmaceutical companies. This expansion is crucial for supporting the growing demand for cell therapies, particularly in cancer and autoimmune disease treatments. The acquisition also highlights the importance of infrastructure redundancy and quality control in the biopharmaceutical industry, ensuring reliable and consistent service delivery.
What's Next?
OrganaBio plans to integrate Excellos' operations over the next 12 months, focusing on maintaining service continuity and enhancing capabilities. The company will work on expanding its service offerings and supporting the growth of its client base. As the integration progresses, OrganaBio aims to streamline operations and improve efficiency, ultimately accelerating the development and delivery of cell therapies to patients. The acquisition positions OrganaBio to play a significant role in the advancement of cell therapy technologies and treatments.
